Annexon Pharmaceuticals has set its sights on late-stage clinical milestones for its C1q-driven complement inhibitors.

Annexon, a clinical-stage biopharmaceutical company, has outlined its strategic priorities for 2024, including late-stage clinical milestones for ANX005 in Guillain-Barré syndrome, ANX007 in geographic atrophy, and the oral small molecule complement inhibitor, ANX1502, for various autoimmune indications. The company's portfolio has been built over a decade of research aimed at stopping C1q-driven inflammation in diseases affecting the body, brain, and eye.

January 08, 2024
5 Articles